Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Chinese Patent Office
Federal Trade Commission
Accenture
Queensland Health
Boehringer Ingelheim
Citi
Cipla
Express Scripts
Daiichi Sankyo

Generated: February 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,410,550

« Back to Dashboard

Summary for Patent: 6,410,550
Title: Aryl fused azapolycyclic compounds
Abstract:Compounds of the formula ##STR1## and their pharmaceutically acceptable salts, wherein R.sup.1, R.sup.2, and R.sup.3 are defined as in the specification, intermediates in the synthesis of such compounds. pharmaceutical compositions containing such compounds and methods of using such compounds, in the treatment of neurological and psychological disorders.
Inventor(s): Coe; Jotham Wadsworth (Niantic, CT), Brooks; Paige Roanne Palmer (North Stonington, CT)
Assignee: Pfizer INC (New York, NY)
Application Number:09/402,010
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 6,410,550

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer Inc CHANTIX varenicline tartrate TABLET;ORAL 021928-001 May 10, 2006 RX Yes No ➤ Sign Up ➤ Sign Up Y Y AID TO SMOKING CESSATION ➤ Sign Up
Pfizer Inc CHANTIX varenicline tartrate TABLET;ORAL 021928-002 May 10, 2006 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y AID TO SMOKING CESSATION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,410,550

PCT Information
PCT FiledNovember 13, 1998PCT Application Number:PCT/IB98/01813
PCT Publication Date:July 15, 1999PCT Publication Number: WO99/35131

Non-Orange Book US Patents Family Members for Patent 6,410,550

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,951,938 Aryl fused azapolycyclic compounds ➤ Sign Up
6,605,610 Aryl fused azapolycyclic compounds ➤ Sign Up
7,205,300 Aryl fused azapolycyclic compounds ➤ Sign Up
6,887,884 Aryl fused azapolycyclic compounds ➤ Sign Up
6,897,310 Aryl fused azapolycyclic compounds ➤ Sign Up
7,144,882 Aryl fused azapolycyclic compounds ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,410,550

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 0162736 ➤ Sign Up
Ukraine 74813 ➤ Sign Up
Ukraine 66825 ➤ Sign Up
Taiwan 513412 ➤ Sign Up
Turkey 200001840 ➤ Sign Up
Tunisia SN98237 ➤ Sign Up
Slovakia 12042002 ➤ Sign Up
Slovakia 286886 ➤ Sign Up
Slovakia 9712000 ➤ Sign Up
Slovenia 1259489 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Chubb
Queensland Health
Baxter
McKesson
Accenture
Healthtrust
Federal Trade Commission
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot